Page 11 - Nature Methods News Today

Kelonia Therapeutics is developing cell therapies made by the in vivo engineering of a patient’s cells made possible by the targeted delivery of a genetic payload. The startup, newly out of stealth with $50M in funding, claims its approach would offer manufacturing and safety advantages over other cell therapy technologies.

In the characterization of nanoparticles, researchers at the Max Planck Institute for the Science of Light (MPL) and Max-Planck-Zentrum für Physik und Medizin (MPZPM) in Erlangen have made a substantial step forward.

10x Genomics, Inc. (NASDAQ:NASDAQ:TXG) Q1 2022 Earnings Conference Call May 04, 2022 04:30 PM ET Company Participants Cassie Corneau - Investor Relations and Strategic Finance Serge Saxonov...

Job: Postdoc Fellow at Massachusetts General Hospital/Harvard Medical School - Martinos Center for Biomedical Imaging at MGH/HMS Charlestown, MA, United States

A new method for monitoring proteins could lead to better drug development

Scientists at Scripps Research have unveiled a new tissue-clearing method for rendering large biological samples transparent.

Scientists started developing tissue-clearing methods about 15 years ago, mainly for tracing whole-brain nerve connections. A Scripps Research team has devised a novel technique that uses a sequential combination of organic solvents and water-based detergents, and makes use of water-based hydrogels to protect those molecules within the tissue that need to be preserved. It often does not require the pumping of solvents through the sample.

Scientists developing new RNA drugs need to understand how proteins bind to these molecules. Eclipsebio’s technology provides that analysis and the biotech startup now has a Series A round of funding to scale up its business.

We study the brain to understand disease, both physical and psychological. Over the last few decades, optical brain imaging has developed into a rich and diverse sub-sector of neuroscience, allowing scientists to investigate real-time brain activity in an unprecedented way.

3D bioprinting and stem cell-based tissue engineering facilitate approaches to chronic kidney disease treatments